/CNW/ - ATMA Journey Centers Inc. ("ATMA"), an Alberta-based company focused on delivering innovative psychedelic-assisted therapies internationally, announced.
Share this article
Share this article
ATMA Journey Centers and SYNTAC Institute collaborate to submit a Group Application for Section 56 Exemption from Health Canada to access psychedelic-assisted therapy
CALGARY, AB, Feb. 2, 2021 /CNW/ -
ATMA Journey Centers Inc. (
ATMA ), an Alberta-based company focused on delivering innovative psychedelic-assisted therapies internationally, announced today that it has submitted a Group Application for Section 56 Exemption to Health Canada on behalf of Canadians struggling with adverse mental and emotional health conditions.
David Harder, Co-CEO of ATMA, said: We ve received close to 300 individual submissions from Canadians over the past 90 days who are struggling deeply with a wide range of psychological, mental and emotional conditions and distress. These are patients who have tried other options that have failed, and COVID-19 has only added to the challenges.
Mind Cure Signs LOI to Acquire an Ownership Interest in Psychedelic Treatment Center ATMA, Selected by Section 56 Exempt Patient for Psilocybin Therapy
News provided by
Share this article
Share this article
The strategic partnership between Mind Cure and ATMA will bridge access to research locations for psychedelic drug research while providing patient data for iSTRYM
, Mind Cure s digital therapeutics platform.
VANCOUVER, BC, Jan. 12, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( Mind Cure or the
LOI ) for strategic investment and commercial cooperation with
ATMA Journey Centers Inc. (
ATMA ), a Calgary-based organization. ATMA is the first commercial treatment center in Canada to announce providing psychedelic-assisted therapy for a section 56 exempt patient. The LOI is intended to help Mind Cure secure an equity position within ATMA, empowering the Company with access to a global release strategy for